Author

E. V. Usachev

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

A. E. Sinyavin· 2 shared A. L. Gintsburg· 2 shared A. N. Zolotar· 2 shared D. A. Kleymenov· 2 shared E. N. Bykonia· 2 shared E. P. Mazunina· 2 shared E. V. Shidlovskaya· 2 shared I. A. Ivanov· 2 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. E. Sinyavin

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Major role of S-glycoprotein in providing immunogenicity and protective immunity in mRNA lipid nanoparticle vaccines based on SARS-CoV-2 structural proteins

E. N. Bykonia, D. A. Kleymenov, V. A. Gushchin, A. E. Sinyavin, E. P. Mazunina, N. Kuznetsova, S. R. Kozlova, A. N. Zolotar, E. V. Shidlovskaya, E. V. Usachev, A. A. Pochtovyi, D. D. Kustova, I. A. Ivanov, S. E. Dmitriev, R. A. Ivanov, , A. L. Gintsburg

This study evaluates mRNA-LNP vaccines encoding SARS-CoV-2 structural proteins, finding that the S protein enhances immune responses to N protein, while M protein has low immunogenicity.

bioRxiv · Dec 30, 2023Immunology

Trivalent mRNA vaccine-candidate against seasonal flu with cross-specific humoral immune response

E. P. Mazunina, V. A. Gushchin, D. A. Kleymenov, A. E. Sinyavin, E. I. Burtseva, M. M. Shmarov, E. A. Mukasheva, E. N. Bykonia, S. R. Kozlova, E. A. Evgrafova, A. N. Zolotar, E. V. Shidlovskaya, E. S. Kirillova, A. S. Krepkaia, E. V. Usachev, , A. L. Gintsburg

This study develops a trivalent mRNA vaccine candidate for seasonal flu, showing higher immunogenicity and cross-specific humoral immune response compared to an inactivated split vaccine.

bioRxiv · Dec 30, 2023Immunology